To determine whether radiofrequency (RF) ablation targeting the tumor-collecting system interface has a durable effect in patients with transfusion-dependent kidney tumor-related hematuria, four patients aged 61-71 years were successfully treated with RF ablation, with a mean follow up of 12 months. Baseline creatinine levels varied from 2.0 mg/dL to 3.7 mg/dL. All patients had received red blood cell transfusions in the days and hours before RF ablation. No subsequent surgical or interventional procedures were required for management of hematuria. Gross hematuria resolved in 24-48 hours in all four patients. Two of the patients are alive with stable renal function and two died of causes unrelated to treatment. RF ablation may be an effective therapeutic option for transfusiondependent cancer-related hematuria in patients with renal insufficiency, solitary kidney, or comorbidities, or after failed conventional therapies in patients who are not candidates for surgery.HEMATURIA related to advanced primary or secondary renal malignancy can be a difficult problem, often complicated by renal insufficiency or comorbidities that may increase the risks and side effects of conventional therapies such as surgery or angiographic embolization. Therapeutic transcatheter embolization has been used as an effective minimally invasive option for management of intractable hematuria (1). However, this procedure can be relatively nonselective and carries the risk of contrast material-induced nephropathy and acute renal failure in patients who already have limited renal function or have undergone nephrectomy. Radiofrequency (RF) ablation has been employed in the management of renal neoplasm-related hematuria (2). In selected patients, RF ablation may prove to be a reasonable alternative to less nephron-sparing techniques. A series of four patients with transfusion-dependent tumor-related gross hematuria were treated successfully with RF ablation, with durable clinical effects.
MATERIALS AND METHODSAfter written informed consent was obtained, all procedures were performed with a Radionics Cool-Tip 200-W RF ablation system (Radionics, Burlington, MA) under conscious sedation with midazolam and fentanyl. In three of four cases, RF ablation procedures were performed percutaneously under ultrasound (US) and computed tomography (CT) guidance, with the remaining procedure performed with US guidance alone with postprocedural CT. Relevant patient data are summarized in the Table. Age varied from 61 to 71 years. Baseline creatinine levels varied from 2.0 mg/dL to 3.7 mg/dL (normal values are 0.6-1.3 mg/dL for women and 0.8-1.5 mg/dL for men). All patients had received red blood cell transfusions in the days and hours before RF ablation.